Last reviewed · How we verify
Prevention of CMV Disease After Organ Transplant
Approved treatments
- Cytotec · Pfizer
Diclofenac inhibits COX-1/COX-2 to reduce prostaglandins; misoprostol is PGE1 analog protecting gastric mucosa. - Cytovene · Roche Palo
GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication. - Zinecard · Pfizer
Zinecard works by binding to metal ions and preventing them from causing damage to DNA during anthracycline treatment. - Cytotec · Generic (originally Searle/Pfizer)
Synthetic prostaglandin E1 analog that protects gastric mucosa by inhibiting acid secretion and stimulating mucus/bicarbonate, also causes uterine contraction. - Zinecard · M.D. Anderson Cancer Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of CMV Disease After Organ Transplant patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of CMV Disease After Organ Transplant treatment landscape brief
- Prevention of CMV Disease After Organ Transplant treatment updates RSS
Frequently asked questions about Prevention of CMV Disease After Organ Transplant
What drugs treat Prevention of CMV Disease After Organ Transplant?
Tracked treatments include Cytotec, Cytovene, Zinecard.
What is the treatment for Prevention of CMV Disease After Organ Transplant?
Standard treatment for Prevention of CMV Disease After Organ Transplant includes Cytotec, Cytovene, Zinecard. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of CMV Disease After Organ Transplant patent cliff · Prevention of CMV Disease After Organ Transplant CI report
- Treatment: Cytotec · Pfizer
- Treatment: Cytovene · Roche Palo
- Treatment: Zinecard · Pfizer
- Treatment: Cytotec · Generic (originally Searle/Pfizer)
- Treatment: Zinecard · M.D. Anderson Cancer Center
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing